Horn C R, Clark T J, Cochrane G M
Department of Thoracic Medicine, United Medical and Dental School, Guy's Hospital, London, U.K.
Respir Med. 1990 Jan;84(1):67-70. doi: 10.1016/s0954-6111(08)80097-2.
Patient compliance with a standardized incremental regimen of inhaled anti-asthma therapy has been assessed in a large, prospective study in general practice. Urine salbutamol estimations were made in 30 patients who had the largest improvement with therapy (mean increase in FEV1 0.45 l above baseline: Responsive) and in 30 patients whose airflow obstruction failed to improve (FEV1-0.14 l: Nonresponsive). The urine salbutamol concentrations rose over the 9 month period in the responsive patients as expected with the incremental doses prescribed, and were significantly higher than urine levels in nonresponsive patients at two dose levels. Poor compliance with prescribed inhaled therapy is an important cause of persistent morbidity from asthma.
在一项大型前瞻性全科医学研究中，对患者遵循标准化递增式吸入抗哮喘治疗方案的情况进行了评估。对30例治疗后改善最明显的患者（第一秒用力呼气容积较基线平均增加0.45升：有反应者）和30例气流阻塞未改善的患者（第一秒用力呼气容积 -0.14升：无反应者）进行了尿沙丁胺醇测定。在9个月期间，有反应的患者尿沙丁胺醇浓度随规定的递增剂量如预期那样升高，并且在两个剂量水平上显著高于无反应患者的尿水平。对规定吸入治疗的依从性差是哮喘持续发病的一个重要原因。
